Related references
Note: Only part of the references are listed.Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease
David Roofeh et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
Dinesh Khanna et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease
Dinesh Khanna et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
Dinesh Khanna et al.
LANCET RESPIRATORY MEDICINE (2020)
Management of systemic sclerosis-associated interstitial lung disease
David Roofeh et al.
CURRENT OPINION IN RHEUMATOLOGY (2019)
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
K. M. Sullivan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial
Geetabali Sircar et al.
RHEUMATOLOGY (2018)
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Dinesh Khanna et al.
LANCET (2016)
Share Paper
